164.19k followers • 15 symbols Watchlist by Yahoo Finance
Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis
Anheuser-Busch InBev SA/NV
Altria Group, Inc.
Molson Coors Beverage Company
The Scotts Miracle-Gro Company
Tilray Brands, Inc.
Cronos Group Inc.
Canopy Growth Corporation
Canopy Growth Corporation
Aurora Cannabis Inc.
Corbus Pharmaceuticals Holdings, Inc.
ETFMG Alternative Harvest ETF
While AbbVie Inc. ( NYSE:ABBV ) shareholders are probably generally happy, the stock hasn't had particularly good run...
A raft of companies have stared down the threat of conservative boycotts with advertising and products celebrating Pride Month.
Altria (NYSE: MO) was once considered a stable dividend play for conservative investors. It's the largest tobacco company in America, it generates steady earnings growth, and it's raised its dividend every year since it spun off its overseas business as Philip Morris International (NYSE: PM) in 2008. Let's see why Altria woefully underperformed the market -- and if it's the right time to buy, sell, or hold its stock.
Tilray Brands, Inc. (TLRY) closed at $1.72 in the latest trading session, marking a +1.18% move from the prior day.
Altria (MO) closed the most recent trading day at $45.33, moving +1.68% from the previous trading session.
As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index prior to the open of trading on Monday, June 19, 2023:
Leading cigarette maker Altria Group (NYSE: MO) saw its net revenue drop 2.9% year over year in the first quarter of 2023, marking the fifth straight quarter of this happening. The stock has been a disaster for investors, down 19% over the past five years while the S&P 500 has climbed 50% during the same period. Does this mean it's time to sell Altria stock and move on?
Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.
Molson Coors brands Coors Light and Miller Lite have grown market share as Bud Light faced a backlash. TD Cowen analyst Vivien Azer says Molson Coors will enjoy “durable market-share momentum.”
In this article, we will discuss the best dividend aristocrat stocks sorted by hedge fund popularity. You can skip our detailed analysis of dividend aristocrats and their past performance, and go directly to read S&P 500 Dividend Aristocrats List: Top 10 Among Hedge Funds. Dividend aristocrats are companies in the S&P 500 that have a […]
In this article, we discuss 14 best annual dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best Annual Dividend Stocks To Buy Now. Dividend stocks are garnering investors’ attention in 2023 as the stock market recovers from […]
Scotts (SMG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Altria (MO) acquires NJOY Holdings and accordingly updates its adjusted EPS guidance for the full-year 2023.
As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio...
Advocates urge continued support of LGBT+ rights despite boycotts of brands such as Target and Bud Light
Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. Coherus' biosimilar will be branded as Yusimry.
Molson Coors (TAP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
The four months between May and August can generate anywhere between 35 and 40 per cent of total annual beer sales. US conservatives are angry with Anheuser-Busch InBev, the Belgian company behind Budweiser. The furore has hit Bud Light sales hard.
Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug. The annual cost of the biosimilar, branded as Yusimry, will be around $13,000, compared with $90,000 for Humira, Coherus said. Coherus has also partnered with Billionaire entrepreneur Mark Cuban's pharmaceuticals startup to sell the biosimilar at $569.27 plus dispensing and shipping fees.
RICHMOND, Va., June 01, 2023--ALTRIA COMPLETES ACQUISITION OF NJOY HOLDINGS, INC.; UPDATES 2023 FULL-YEAR EARNINGS GUIDANCE
When anti-LGBTQ+ activists went after Target for selling Pride merchandise, they guessed the company would cave. They were right.
The underwhelming Canadian pot market has made it difficult for these businesses to generate any consistent revenue growth.
British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.
Plans to Exit Existing U.S. hemp-derived CBD Operations Intends to Launch Lord Jones® Brand in the Canadian Adult-use Market in Q4 2023 TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced its decision to streamline its operating structure by winding down and exiting its existing U.S. hemp-derived CBD-focused operations by the end of the second quarter of 2023. Cronos has made